Vaccination with tumor-ganglioside glycomimetics activates a selective immunity that affords cancer therapy

From National Research Council Canada

Download
  1. (PDF, 3.4 MiB)
  2. (PDF, 1.5 MiB)
DOIResolve DOI: https://doi.org/10.1016/j.chembiol.2019.03.018
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: 1; Search for: 1; Search for: ; Search for: ; Search for: ; Search for:
Affiliation
  1. National Research Council of Canada. Human Health Therapeutics
FormatText, Article
Subjectganglioside; glycomimetic; immunity; vaccine; cancer therapy
Abstract
Publication date
PublisherElsevier
Cell Press
Licence
In
LanguageEnglish
Peer reviewedYes
NRC numberNRC-HHT_53421
Export citationExport as RIS
Report a correctionReport a correction (opens in a new tab)
Record identifier20aa9f9e-4b76-4246-8cb4-3dd6e091ba2a
Record created2020-12-08
Record modified2021-09-24
Date modified: